Toxicological Risk Assessment for Medical Devices & Materials

A toxicological risk assessment takes identified and quantified substances, compares estimated patient exposure with tolerable levels derived from toxicological data, and documents whether the released substances present an unacceptable risk.

From chemical data to an exposure-based conclusion

Identify and quantify relevant constituents, explain analytical uncertainty and unidentified peaks, then justify patient exposure against appropriate toxicological information. Report assumptions, sensitive populations, duration, uncertainty and remaining evidence gaps. A list of detected chemicals is not a toxicological assessment, and chemistry does not automatically replace all biological endpoints.

What to include in your buyer brief

Start with the decision the work must support. Unknown details can be clarified after the initial inquiry.

Product, materials/formulation, patient or drug contact, contact duration, intended use and target market; identify changed materials, suppliers or processes.
Finished configuration, sample count and lots, sterilization modality/cycles, aging and storage history; justify worst-case variants and destructive allocations.
Existing evaluation plan, drawings, specifications, methods/editions, previous reports and acceptance criteria; send confidential files only through the private intake.
Required report, quality/accreditation scope, budget range, location, shipping constraints and decision deadline; ask the provider to explain exclusions and subcontracted work.

Reference versus candidate medical plastics and colorants

Compare the reference and candidate finished components, documented resin identity when available, pigment/dye or additive changes, manufacturing and cleaning/sterilization histories, and actual exposure. Unknown composition, sample allocation and test panels remain questions to resolve—not inferred facts. Material identification and color comparison do not establish biological safety.

Propose methods around the evidence gap

Ask the provider whether FTIR, DSC or other material identification, targeted chemistry, extraction studies and toxicological interpretation can answer the comparison question. These are possible proposals, not prescribed tests. Biological compatibility, chemical/material resistance and product interactions are different scopes. A qualified evaluator should justify existing evidence, chemical characterization and any targeted biological testing after a material or colorant change.

Plan, evaluate and test: separate the deliverables

A biological evaluation plan (BEP) identifies contact, duration, existing evidence and gaps; a biological evaluation report (BER) integrates the evidence and rationale. An endpoint laboratory report answers a scoped test question, not the entire biological evaluation. A qualified evaluator should justify endpoint selection and use of prior evidence; not every material change requires every test.

Chemistry versus toxicological interpretation

ISO 10993-18 chemical characterization addresses what substances may be present or released and the analytical coverage/limitations. ISO 10993-17 toxicological risk assessment interprets constituent exposure, toxicological evidence and uncertainty in the device-use context. A chemical list alone is not a safety conclusion, and a TRA cannot cure poorly justified extraction or uncharacterized analytical gaps.

Extractables, leachables and residuals

Forced extractables explore potential release under justified exaggerated conditions; actual or simulated-use leachables address release under relevant contact conditions. Neither automatically substitutes for the other. Distinguish manufacturing residuals such as monomers, solvents and processing aids from sterilization residuals such as ethylene oxide and relevant reaction products. Define analytical targets, exposure assumptions, recovery, reporting thresholds and uncertainties with the provider; no universal panel.

Sample considerations

Assessment quality depends on the underlying analytical data — extraction conditions, identification confidence and thresholds all matter.
Provide clinical use information: patient population, contact duration, frequency and worst-case exposure.
Unidentified peaks limit what can be concluded; expect the assessor to ask for further analytical work.

Laboratories with relevant capabilities

Nelson Labs Europe (Leuven, Flemish Brabant) — Toxicological risk assessment
WuXi AppTec Medical Device Testing (Suzhou, Jiangsu) — Profile summary mentions “toxicological risk assessment”

Frequently asked questions

Is this laboratory work?: It is an expert assessment built on laboratory data. Some laboratories provide both the chemical characterisation and the assessment; others work with independent toxicologists.